Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
subcutaneous omacetaxine mepesuccinate (15) 15
index medicus (14) 14
chronic myelogenous leukemia (13) 13
oncology (12) 12
tyrosine kinase inhibitors (11) 11
chronic myeloid leukemia (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (8) 8
chronic myeloid-leukemia (7) 7
antineoplastic agents - therapeutic use (6) 6
hematology (6) 6
homoharringtonine (6) 6
adult (5) 5
aged (5) 5
antineoplastic agents - pharmacology (5) 5
antineoplastic agents, phytogenic - administration & dosage (5) 5
female (5) 5
follow-up (5) 5
harringtonines - administration & dosage (5) 5
hemic and lymphatic diseases (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - genetics (5) 5
male (5) 5
middle aged (5) 5
pharmacology & pharmacy (5) 5
research (5) 5
tyrosine (5) 5
article (4) 4
chromosome-positive leukemias (4) 4
chronic-phase (4) 4
dasatinib (4) 4
domain mutations (4) 4
imatinib (4) 4
injections, subcutaneous (4) 4
minimal residual disease (4) 4
nilotinib (4) 4
patients receiving imatinib (4) 4
protein kinase inhibitors - therapeutic use (4) 4
review (4) 4
treatment outcome (4) 4
acute lymphoblastic-leukemia (3) 3
animals (3) 3
antineoplastic agents, phytogenic - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
bcr-abl (3) 3
bcr-abl mutations (3) 3
bcr-abl1 (3) 3
cancer (3) 3
cml (3) 3
complete cytogenetic response (3) 3
diagnosed chronic-phase (3) 3
down-regulation (3) 3
harringtonines - adverse effects (3) 3
health aspects (3) 3
imatinib mesylate (3) 3
imatinib resistance (3) 3
infusions, subcutaneous (3) 3
leukemia (3) 3
leukemia, myeloid, chronic-phase - drug therapy (3) 3
mutation (3) 3
neoplasms - drug therapy (3) 3
prognosis (3) 3
protein kinase inhibitors - adverse effects (3) 3
protein kinase inhibitors - pharmacology (3) 3
signal transduction - drug effects (3) 3
stem-cell transplantation (3) 3
abridged index medicus (2) 2
aged, 80 and over (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
apoptosis (2) 2
biochemistry & molecular biology (2) 2
cancer research (2) 2
care and treatment (2) 2
chemotherapy (2) 2
chromosomes (2) 2
chronic lymphocytic-leukemia (2) 2
colony-stimulating factor (2) 2
disease progression (2) 2
drug approval (2) 2
drug resistance, neoplasm (2) 2
drug resistance, neoplasm - drug effects (2) 2
drug therapy (2) 2
hematologic neoplasms - drug therapy (2) 2
hematology, oncology and palliative medicine (2) 2
imatinib mesylate therapy (2) 2
interferon-alpha (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - pathology (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - therapy (2) 2
leukemia, myeloid, chronic-phase - mortality (2) 2
lymphomas (2) 2
methods (2) 2
neoplasms - pathology (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
omacetaxine mepesuccinate (2) 2
oncology, experimental (2) 2
open-label (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
by Cortes, Jorge and Lipton, Jeff H and Rea, Delphine and Digumarti, Raghunadharao and Chuah, Charles and Nanda, Nisha and Benichou, Annie-Claude and Craig, Adam R and Michallet, Mauricette and Nicolini, Franck E and Kantarjian, Hagop and Omacetaxine 202 Study Grp and Omacetaxine 202 Study Group
Blood, ISSN 0006-4971, 09/2012, Volume 120, Issue 13, pp. 2573 - 2580
Chronic myeloid leukemia (CML) patients with the BCR-ABL T315I mutation do not benefit from therapy with currently approved tyrosine kinase inhibitors.... 
CHRONIC MYELOGENOUS LEUKEMIA | SEMISYNTHETIC HOMOHARRINGTONINE | IMATINIB-RESISTANT CML | ACUTE LYMPHOBLASTIC-LEUKEMIA | DOWN-REGULATION | CHROMOSOME-POSITIVE LEUKEMIAS | COMPLETE CYTOGENETIC RESPONSE | ABL KINASE DOMAIN | STEM-CELL TRANSPLANTATION | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Salvage Therapy | Male | Survival Rate | Protein Kinase Inhibitors - adverse effects | Mutation - genetics | Dose-Response Relationship, Drug | Leukemia, Myeloid, Chronic-Phase - mortality | Antineoplastic Agents, Phytogenic - administration & dosage | Fusion Proteins, bcr-abl - genetics | Injections, Subcutaneous | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged, 80 and over | Harringtonines - administration & dosage | Adult | Female | Aged | Drug Resistance, Neoplasm - drug effects | Clinical Trials and Observations | Myeloid Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
by Nemunaitis, John and Nemunaitis, John and Mita, Alain and Mita, Alain and Stephenson, Joe and Stephenson, Joe and Mita, Monica M and Mita, Monica M and Sarantopoulos, John and Sarantopoulos, John and Padmanabhan-Iyer, Swami and Padmanabhan-Iyer, Swami and Nanda, Nisha and Nanda, Nisha and Gleich, Lyon and Gleich, Lyon and Benichou, Annie-Claude and Benichou, Annie-Claude and Craig, Adam and Craig, Adam
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2013, Volume 71, Issue 1, pp. 35 - 41
Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation... 
Omacetaxine mepesuccinate | Medicine & Public Health | Homoharringtonine | Subcutaneous | Oncology | Cancer Research | Cephalotaxine | Phase 1 | Pharmacology/Toxicology | RESPONSE CRITERIA | ONCOLOGY | IMATINIB | PHARMACOLOGY & PHARMACY | CHRONIC MYELOID-LEUKEMIA | INTERNATIONAL WORKING GROUP | Humans | Middle Aged | Half-Life | Harringtonines - adverse effects | Long QT Syndrome - chemically induced | Male | Hematologic Neoplasms - pathology | Thrombocytopenia - chemically induced | Neoplasms - drug therapy | Tissue Distribution | Antineoplastic Agents, Phytogenic - administration & dosage | Injections, Subcutaneous | Harringtonines - blood | Harringtonines - pharmacokinetics | Harringtonines - administration & dosage | Hematologic Neoplasms - drug therapy | Adult | Female | Aged | Neoplasms - pathology | Neutropenia - chemically induced | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives
by Heiblig, M and Sobh, M and Nicolini, F.E
Leukemia Research, ISSN 0145-2126, 2014, Volume 38, Issue 10, pp. 1145 - 1153
Highlights • Omacetaxine mepesuccinate (OMA) demonstrates specific activity in CML. • Recent studies demonstrate the activity of OMA even in poor prognosis... 
Hematology, Oncology and Palliative Medicine | Chronic phase CML | T315I | Imatinib | Imatinib resistance | BCR-ABL mutation | CHRONIC MYELOGENOUS LEUKEMIA | SEMISYNTHETIC HOMOHARRINGTONINE | DOWN-REGULATION | AURORA KINASE | BCR-ABL INHIBITOR | PHASE-II TRIAL | INTERFERON-ALPHA | ONCOLOGY | MOLECULAR RESPONSE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | IMATINIB MESYLATE | Antineoplastic Agents, Phytogenic - administration & dosage | Animals | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Harringtonines - administration & dosage | Drug Resistance, Neoplasm - drug effects | Infusions, Subcutaneous | Tyrosine | Phenols
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
by Cortes, J and Digumarti, R and Parikh, P.M and Wetzler, M and Lipton, J.H and Hochhaus, A and Craig, A.R and Benichou, A.‐C and Nicolini, F.E and Kantarjian, H.M and Omacetaxine 203 Study Grp and Omacetaxine 203 Study Group and the Omacetaxine 203 Study Group
American Journal of Hematology, ISSN 0361-8609, 05/2013, Volume 88, Issue 5, pp. 350 - 354
Omacetaxine mepesuccinate (omacetaxine) is a first‐in‐class cephalotaxine with a unique mode of action, independent of BCR‐ABL, that has shown promising... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | APOPTOSIS | THERAPY | BCR-ABL | IMATINIB | DOWN-REGULATION | HOMOHARRINGTONINE | HEMATOLOGY | FAILURE | NILOTINIB | Drug Resistance, Multiple | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Harringtonines - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Harringtonines - therapeutic use | Protein Synthesis Inhibitors - administration & dosage | Hematopoiesis - drug effects | Maintenance Chemotherapy - adverse effects | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Harringtonines - administration & dosage | Adult | Bone Marrow Cells - drug effects | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - adverse effects | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Bone Marrow Cells - pathology | Induction Chemotherapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged | Drug Monitoring | Protein Synthesis Inhibitors - adverse effects | Protein Synthesis Inhibitors - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Phenols | Research | Chronic myeloid leukemia | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
by Cortes, Jorge E and Nicolini, Franck E and Wetzler, Meir and Lipton, Jeffrey H and Akard, Luke and Craig, Adam and Nanda, Nisha and Benichou, Annie-Claude and Leonoudakis, Janis and Khoury, H. Jean and Hochhaus, Andreas and Baccarani, Michele and Kantarjian, Hagop M
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2013, Volume 13, Issue 5, pp. 584 - 591
Micro-Abstract This analysis evaluated the protein synthesis inhibitor omacetaxine mepesuccinate (“omacetaxine”) in previously treated patients with chronic... 
Hematology, Oncology and Palliative Medicine | Nilotinib | Resistance | Dasatinib | Intolerance | Homoharringtonine | CHRONIC MYELOGENOUS LEUKEMIA | THERAPY FAILURE | BCR-ABL | FOLLOW-UP | DURABLE CYTOGENETIC RESPONSES | ONCOLOGY | END-POINT | DIAGNOSED CHRONIC-PHASE | CHROMOSOME-POSITIVE LEUKEMIAS | HEMATOLOGY | RESISTANT CML | Piperazines - administration & dosage | Drug Administration Schedule | Pyrimidines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Harringtonines - adverse effects | Male | Treatment Outcome | Imatinib Mesylate | Infusions, Subcutaneous | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Benzamides - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Harringtonines - administration & dosage | Adult | Female | Aged | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
by Baccarani, Michele and Deininger, Michael W and Rosti, Gianantonio and Hochhaus, Andreas and Soverini, Simona and Apperley, Jane F and Cervantes, Francisco and Clark, Richard E and Cortes, Jorge E and Guilhot, François and Hjorth-Hansen, Henrik and Hughes, Timothy P and Kantarjian, Hagop M and Kim, Dong-Wook and Larson, Richard A and Lipton, Jeffrey H and Mahon, François-Xavier and Martinelli, Giovanni and Mayer, Jiri and Müller, Martin C and Niederwieser, Dietger and Pane, Fabrizio and Radich, Jerald P and Rousselot, Philippe and Saglio, Giuseppe and Saußele, Susanne and Schiffer, Charles and Silver, Richard and Simonsson, Bengt and Steegmann, Juan-Luis and Goldman, John M and Hehlmann, Rüdiger and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper and Hematologi
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A... 
TYROSINE KINASE INHIBITORS | CHRONIC MYELOGENOUS LEUKEMIA | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | BCR-ABL1 TRANSCRIPT LEVELS | DIAGNOSED CHRONIC-PHASE | COMPLETE MOLECULAR REMISSION | MAJOR CYTOGENETIC RESPONSE | PATIENTS RECEIVING IMATINIB | ARTERIAL OCCLUSIVE DISEASE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Dasatinib | Prognosis | Europe | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Treatment Outcome | Antineoplastic Agents - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Piperazines - therapeutic use | Thiazoles - therapeutic use | Imatinib Mesylate | Randomized Controlled Trials as Topic | Stem Cell Transplantation | Benzamides - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - metabolism | Review | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Metabolite profiling of C-14-omacetaxine mepesuccinate in plasma and excreta of cancer patients
by Nijenhuis, CM and Lucas, L and Rosing, H and Robertson, P and Hellriegel, ET and Schellens, JHM and Beijnen, JH
XENOBIOTICA, ISSN 0049-8254, 12/2016, Volume 46, Issue 12, pp. 1122 - 1132
1. Omacetaxine mepesuccinate (hereafter referred to as omacetaxine) is a protein translation inhibitor approved by the US Food and Drug Administration for... 
MOLECULAR-BIOLOGY | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | CHRONIC-PHASE | homoharringtonine | DOMAIN MUTATIONS | MASS-BALANCE | metabolites | CHRONIC MYELOID-LEUKEMIA | TYROSINE KINASE INHIBITORS | Disposition | pharmacokinetics | PHARMACOLOGY & PHARMACY | metabolism | TOXICOLOGY | mepesuccinate | metabolite profiling | omacetaxine | IMATINIB RESISTANCE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology
by Radich, JP and Deininger, M and Abboud, CN and Altman, JK and Berman, E and Bhatia, R and Bhatnagar, B and Curtin, P and DeAngelo, DJ and Gotlib, J and Hobbs, G and Jagasia, M and Kantarjian, HM and Maness, L and Metheny, L and Moore, JO and Pallera, A and Pancari, P and Patnaik, M and Purev, E and Rose, MG and Shah, NP and Smith, BD and Snyder, DS and Sweet, KL and Talpaz, M and Thompson, J and Yang, DT and Gregory, KM and Sundar, H
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 09/2018, Volume 16, Issue 9, pp. 1108 - 1135
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and... 
CHRONIC MYELOGENOUS LEUKEMIA | TYROSINE KINASE INHIBITORS | CHROMOSOME-NEGATIVE METAPHASES | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | ONCOLOGY | STANDARD-DOSE IMATINIB | IN-SITU HYBRIDIZATION | COMPLETE CYTOGENETIC RESPONSE | PATIENTS RECEIVING IMATINIB | IMATINIB MESYLATE THERAPY | MINIMAL RESIDUAL DISEASE
Journal Article
Details down arrow
9. Full Text Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options
by Meenakshi Sundaram, Daniel Nisakar and Jiang, Xiaoyan and Brandwein, Joseph M and Valencia-Serna, Juliana and Remant, K.C and Uludağ, Hasan
Drug Discovery Today, ISSN 1359-6446, 07/2019, Volume 24, Issue 7, pp. 1355 - 1369
Chronic myeloid leukemia cells are armed with several resistance mechanisms that can make current drugs ineffective. A better understanding of resistance... 
CHRONIC MYELOGENOUS LEUKEMIA | KINASE INHIBITOR RESISTANCE | STEM-CELLS | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | BONE-MARROW MICROENVIRONMENT | COLONY-STIMULATING FACTOR | ACUTE LYMPHOBLASTIC-LEUKEMIA | BCR-ABL GENE | PHARMACOLOGY & PHARMACY | BETA-1-INTEGRIN MEDIATED ADHESION | IMATINIB RESISTANCE | Tyrosine | Care and treatment | Pharmacy | Medical genetics | Drugstores | Chronic myeloid leukemia | Drug resistance | Health aspects | Biomedical engineering
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Optimizing Patient Care in Chronic Phase Chronic Myelogenous Leukemia: A Multidisciplinary Approach
by Sundar, H and Radich, J
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 01/2016, Volume 14, Issue 14 Suppl 1, pp. S1 - S6
Chronic myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome arising from a reciprocal translocation between chromosomes... 
TYROSINE KINASE INHIBITORS | DOMAIN | INTOLERANT | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | CML | ONCOLOGY | IMATINIB | FOLLOW-UP | DASATINIB | NILOTINIB | CHRONIC MYELOID-LEUKEMIA
Journal Article
Details down arrow
11. Full Text Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
by Massimino, Michele and Stella, Stefania and Tirrò, Elena and Romano, Chiara and Pennisi, Maria Stella and Puma, Adriana and Manzella, Livia and Zanghì, Antonino and Stagno, Fabio and Di Raimondo, Francesco and Vigneri, Paolo
Molecular Cancer, ISSN 1476-4598, 02/2018, Volume 17, Issue 1, pp. 56 - 15
The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large... 
CML | BCR-ABL1 | Therapeutic strategies | Immunological approaches | CHRONIC MYELOGENOUS LEUKEMIA | HEDGEHOG PATHWAY | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | CHRONIC-PHASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BCR-ABL | FARNESYL TRANSFERASE INHIBITOR | CANCER STEM-CELLS | TYROSINE KINASE INHIBITORS | RESISTANT CML CELLS | ONCOLOGY | MINIMAL RESIDUAL DISEASE | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Treatment Outcome | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Molecular Targeted Therapy | Biomarkers, Tumor | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Tyrosine | Development and progression | Care and treatment | Research | Chronic myeloid leukemia | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015
by Thompson, Philip A., MBBS and Kantarjian, Hagop M., MD and Cortes, Jorge E., MD
Mayo Clinic Proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 10, pp. 1440 - 1454
Abstract Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In... 
Internal Medicine | CHRONIC MYELOGENOUS LEUKEMIA | TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | SUBCUTANEOUS OMACETAXINE MEPESUCCINATE | BONE-MARROW-TRANSPLANTATION | EARLY CHRONIC-PHASE | CHROMOSOME-POSITIVE LEUKEMIAS | COMPLETE CYTOGENETIC RESPONSE | IMATINIB MESYLATE THERAPY | MINIMAL RESIDUAL DISEASE | HIGH-DOSE IMATINIB | Diagnosis, Differential | Prognosis | Protein Kinase Inhibitors - classification | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Clinical Protocols | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Patient Outcome Assessment | Disease Progression | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Protein Kinase Inhibitors - pharmacology | Philadelphia Chromosome
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights